Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) will release its earnings data before the market opens on Tuesday, August 13th. Analysts expect Praxis Precision Medicines to post earnings of ($2.39) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its earnings results on Monday, May 13th. The company reported ($2.84) EPS for the quarter, missing analysts’ consensus estimates of ($2.01) by ($0.83). Praxis Precision Medicines had a negative return on equity of 101.99% and a negative net margin of 5,711.85%. The firm had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $2.75 million. On average, analysts expect Praxis Precision Medicines to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.
Praxis Precision Medicines Stock Up 3.0 %
Shares of Praxis Precision Medicines stock traded up $1.60 on Tuesday, hitting $55.12. The company’s stock had a trading volume of 313,121 shares, compared to its average volume of 283,125. The firm has a fifty day moving average price of $46.65 and a 200-day moving average price of $48.02. Praxis Precision Medicines has a 52-week low of $12.90 and a 52-week high of $67.21. The company has a market capitalization of $942.99 million, a P/E ratio of -3.47 and a beta of 2.73.
Analyst Upgrades and Downgrades
View Our Latest Stock Analysis on Praxis Precision Medicines
About Praxis Precision Medicines
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
See Also
- Five stocks we like better than Praxis Precision Medicines
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Ride Out The Recession With These Dividend Kings
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Most Volatile Stocks, What Investors Need to Know
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.